Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. - Wikidata - wikimedia - TriplyDB

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

http://www.wikidata.org/entity/Q39506775

about

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Identification of a cell of origin for human prostate cancer Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort The genomic complexity of primary human prostate cancer New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer DNA damage response and prostate cancer: defects, regulation and therapeutic implications The mutational landscape of prostate cancer Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue Translating insights of AR signaling from mouse models Genetically engineered mouse models of prostate cancer Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model ERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signaling Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer Integrative genomic profiling of human prostate cancer ERG induces taxane resistance in castration-resistant prostate cancer ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technology Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation.Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.An oncogenic role for ETV1 in melanoma.Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.Mouse models of prostate cancer: picking the best model for the question.

P2860

Q21091136-885B3EB8-6ACC-45EE-B280-05C4B4EC0659 Q24302687-D6816FCE-AC85-43C1-9D68-968168C0EE53 Q24594400-F2A7C37F-0CBB-4BD5-AC72-A4B160948B6D Q24606772-00C9AC1F-48C3-4594-9C41-752E2CB18569 Q24617949-A7F63F94-C6DC-4B34-9CD6-43AF5A2A447D Q24620308-45D43C21-9927-46FB-943F-23256ED17434 Q26829155-79CF247E-FBB6-4080-973C-54BB5D449911 Q26851631-57400815-1534-439A-A525-BB1D5E100CFF Q26997884-BEEB4BC3-2B2F-492E-B6EB-CDAE9F22C343 Q27014822-093851E5-B9E3-4B1D-9C4C-9EE3577C2AFB Q27026768-7E2E3A23-8874-4799-BC45-D9C8B6F609EA Q27308107-FFAA085A-673E-447D-A065-B4B5D4AE0438 Q27311359-CA05E477-9121-4C39-91F6-778D3E6C1BAD Q27322372-73287878-666E-4712-9B2F-D2CE5B807FC5 Q28383769-12F77C20-DBF4-410B-9EB4-B30028E7BEFF Q28388722-8C54DFE8-0B95-46A2-8955-E0C76A989A8B Q28478908-776172CB-E6FE-49DE-807A-A0E5C9F9C533 Q28484833-636631F9-7269-4C51-87AB-BF682C1481E5 Q28546607-1E061BA3-FB88-4589-87AB-08228D5CF1FE Q29619905-4F0B3D44-6814-487E-BAA7-2C2F304E9B10 Q30602046-FC9A539A-7BA0-4939-BA4F-5774D7CF5674 Q31005436-5F08493F-AE36-43F5-90D0-3CE046E7DE3C Q31042968-409DA841-CE78-4F18-B640-1BBAF936E76A Q33390454-3E28E66A-238C-43BF-BB25-E6172F0B720A Q33507490-D7C775F7-FB24-43F3-807C-974D7647607D Q33574512-66852F30-F70F-43DF-870D-7581BAB94AD0 Q33597010-93DF9D44-69C1-46D8-BAFB-8537BEE54055 Q33608762-F281759D-E894-497F-A6DC-23589A202D48 Q33677421-E858B41C-7D8D-4320-B960-96433F4661EA Q33682349-A5708FBF-DC44-4E88-A9C6-4D3973CE5F53 Q33692377-5BBB0381-EB9C-40BA-93CF-49EC660C22BE Q33699391-A7F69C59-64C9-452A-93BA-366B72B6E3C3 Q33723651-F25243BA-0DF0-409E-B962-45E8AB13096C Q33756912-045FC6CB-D68A-4E03-B483-256CBFB31988 Q33805953-71CA4329-4F90-4000-BA51-CCBF86B5C5F9 Q33852664-308D575B-FCD9-43EF-9404-ED62AF947FE0 Q33862890-B19CDBAA-6A09-47AD-833A-CA65FECAF2C8 Q33924077-52E86878-41B8-4B52-947B-E683FEE23E58 Q33936343-D11EFF9D-0209-45D3-9D5D-4623C33A0D8B Q33940867-CBB5E942-64F0-4E9E-A716-AE36D94481D2

P2860

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

http://www.wikidata.org/entity/Q39506775

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Aberrant ERG expression cooper ...... r progression in the prostate.

@en

Aberrant ERG expression cooper ...... r progression in the prostate.

@nl

type

label

Aberrant ERG expression cooper ...... r progression in the prostate.

@en

Aberrant ERG expression cooper ...... r progression in the prostate.

@nl

prefLabel

Aberrant ERG expression cooper ...... r progression in the prostate.

@en

Aberrant ERG expression cooper ...... r progression in the prostate.

@nl

P1433

Q39506775-8BD663B6-FEAA-4A8A-A36E-3A4BDFBB4A0A

P1476

Q39506775-1E12DED9-3D99-40A3-896D-5257F41B2211

P2093

Q39506775-000ABF03-6EF9-4A6E-BF43-35408EA89B69

Q39506775-188951A7-75DD-4CA4-9D62-F9736169082E

Q39506775-45D8D1BA-88FE-41C1-BF70-9FC0D9637EEF

Q39506775-4D66827C-84E9-44D9-AE35-9F47ADA69245

Q39506775-5B27492C-2ED6-44E3-ADBF-1B99548CD5E3

Q39506775-68786B39-D4B3-4C17-8C26-69BE2C8F5180

Q39506775-6C49CB36-94DF-4A6C-AEB7-DD1E617BB6F4

Q39506775-7D6AC4CB-2B08-46F8-9FED-71F7CF7368B1

Q39506775-839CE61D-A7C3-425C-A42D-78AA7681511B

Q39506775-A8B95ACC-BA8C-4485-B25E-A1C5F6361669

P2860

Q39506775-0BFAB14B-604B-4F55-A7AA-551B19478113

Q39506775-1A4D83AD-2DD1-477A-B139-1DEF95111B5F

Q39506775-2E3F2FC6-A4F0-4679-B5FA-69073369FB0D

Q39506775-5444D7DE-523D-45A1-AEFF-C51BEFFEE16D

Q39506775-5DAF2AD1-8F6D-4D07-B4EE-2C03380D2ADF

Q39506775-656923B7-4D3B-4A85-BC22-BB775C290CDC

Q39506775-672DD2B0-964E-417F-8F83-E6CCDCD40383

Q39506775-675860BD-F291-481B-AD29-09A9E0D1FBFB

Q39506775-6C591F30-11B8-4848-B974-BD70166CFBFB

Q39506775-74B67B78-466B-440B-B1AA-C8CEEA308714

P2888

Q39506775-A61B3735-43EB-4774-B6B0-05BF2385F569

P304

Q39506775-7652ACFF-2080-41C5-900F-340814EA3A27

P31

Q39506775-EF94EAB7-E166-46C5-A974-B26A93100CE1

P356

Q39506775-7AD46841-C9F1-4008-BE4C-A6D199559262

P407

Q39506775-E85B7B4F-93C0-49BA-B260-4F05E873A8E3

P433

Q39506775-024D5BFD-D42F-45F9-9BB1-5961727E585A

P478

Q39506775-CBACB3D6-6FED-4412-981D-23C414BAB957

P50

Q39506775-11FAE3BA-33EF-47F9-A7D0-6886F2B60A1B

Q39506775-4714E5E7-E629-4FE9-9442-392C0D28398F

P577

Q39506775-6B98646B-75FA-422E-8FA6-675CD1710760

P5875

Q39506775-D4FC09AE-3385-4B99-A575-5723A7A95DF4

P6179

Q39506775-344E0B4A-D70F-4205-9AD6-DA739F0D1A27

P698

Q39506775-A6FCCE87-DF4A-421E-9051-19E01C64FD52

P932

Q39506775-01D2D019-C79D-45D6-834C-C259C77EBEDF

P356

P1433

Nature Genetics

P1476

Aberrant ERG expression cooper ...... r progression in the prostate.

@en

P2093

Andrea Alimonti

http://www.w3.org/2001/XMLSchema#string

Anuradha Gopalan

http://www.w3.org/2001/XMLSchema#string

Arkaitz Carracedo

http://www.w3.org/2001/XMLSchema#string

Brett S Carver

http://www.w3.org/2001/XMLSchema#string

Caterina Nardella

http://www.w3.org/2001/XMLSchema#string

Jennifer Tran

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

Safa Shaikh

http://www.w3.org/2001/XMLSchema#string

Shohreh Varmeh

http://www.w3.org/2001/XMLSchema#string

William Gerald

http://www.w3.org/2001/XMLSchema#string

P2860

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Pten dose dictates cancer progression in the prostate

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

SIR2 and SIR4 interactions differ in core and extended telomeric heterochromatin in yeast.

Role of the TMPRSS2-ERG gene fusion in prostate cancer

Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration

Pten is essential for embryonic development and tumour suppression

Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

P2888

P304

619-624

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NG.370

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Carlos Cordon-Cardo

Pier Paolo Pandolfi

P577

2009-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24361808

http://www.w3.org/2001/XMLSchema#string

P6179

1049961568

http://www.w3.org/2001/XMLSchema#string

P698

19396168

http://www.w3.org/2001/XMLSchema#string

P932

2835150

http://www.w3.org/2001/XMLSchema#string